These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 30409995)

  • 21. Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation.
    Raimondi L; De Luca A; Amodio N; Manno M; Raccosta S; Taverna S; Bellavia D; Naselli F; Fontana S; Schillaci O; Giardino R; Fini M; Tassone P; Santoro A; De Leo G; Giavaresi G; Alessandro R
    Oncotarget; 2015 May; 6(15):13772-89. PubMed ID: 25944696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.
    Oyajobi BO; Franchin G; Williams PJ; Pulkrabek D; Gupta A; Munoz S; Grubbs B; Zhao M; Chen D; Sherry B; Mundy GR
    Blood; 2003 Jul; 102(1):311-9. PubMed ID: 12649140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.
    Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
    Leuk Lymphoma; 2014 Apr; 55(4):911-9. PubMed ID: 23915193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myeloma bone disease.
    Sezer O
    Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The multiple myeloma bone eco-system and its relation to oncogenesis.
    Bataille R
    Morphologie; 2015 Jun; 99(325):31-7. PubMed ID: 26005000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease.
    Muller J; Bolomsky A; Dubois S; Duray E; Stangelberger K; Plougonven E; Lejeune M; Léonard A; Marty C; Hempel U; Baron F; Beguin Y; Cohen-Solal M; Ludwig H; Heusschen R; Caers J
    Haematologica; 2018 Aug; 103(8):1359-1368. PubMed ID: 29748441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
    Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
    Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
    Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
    Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.
    Terpos E
    Leuk Res; 2010 Jun; 34(6):700-1. PubMed ID: 20074800
    [No Abstract]   [Full Text] [Related]  

  • 30. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
    Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
    Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
    Kaiser MF; Heider U; Mieth M; Zang C; von Metzler I; Sezer O
    Eur J Haematol; 2013 Apr; 90(4):263-72. PubMed ID: 23311753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple myeloma-derived exosomes inhibit osteoblastic differentiation and improve IL-6 secretion of BMSCs from multiple myeloma.
    Liu Z; Liu H; Li Y; Shao Q; Chen J; Song J; Fu R
    J Investig Med; 2020 Jan; 68(1):45-51. PubMed ID: 31784427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteoblastogenesis and tumor growth in myeloma.
    Yaccoby S
    Leuk Lymphoma; 2010 Feb; 51(2):213-20. PubMed ID: 20038269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
    Deleu S; Lemaire M; Arts J; Menu E; Van Valckenborgh E; Vande Broek I; De Raeve H; Coulton L; Van Camp B; Croucher P; Vanderkerken K
    Cancer Res; 2009 Jul; 69(13):5307-11. PubMed ID: 19531653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
    Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
    Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ceramide pathway is involved in the survival, apoptosis and exosome functions of human multiple myeloma cells in vitro.
    Cheng Q; Li X; Wang Y; Dong M; Zhan FH; Liu J
    Acta Pharmacol Sin; 2018 Apr; 39(4):561-568. PubMed ID: 28858294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodeling in vivo in myeloma bone disease.
    Liu H; Peng F; Liu Z; Jiang F; Li L; Gao S; Wang G; Song J; Ruan E; Shao Z; Fu R
    Int J Oncol; 2017 Feb; 50(2):631-639. PubMed ID: 28035364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of Myeloma Bone Lesions.
    Du JS; Yen CH; Hsu CM; Hsiao HH
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the bone microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Metab; 2010 May; 28(3):244-50. PubMed ID: 20127498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dickkopf-1: a suitable target for the management of myeloma bone disease.
    Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
    Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.